The company anticipates submitting a biologics licence application for accelerated approval in the US in early 2026.

The orphan drug designation is particularly noteworthy as it can provide Dyne with a range of benefits, including reduced regulatory fees, assistance with clinical protocols, eligibility for research ...

Dyne Therapeutics (DYN) announced that the European Commission has granted orphan drug designation for DYNE-251 for the treatment of Duchenne ...

Dyne anticipates filing a Biologics License Application (BLA) submission for US accelerated approval in early 2026.

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the importance of early diagnosis of muscular dystrophy.

ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

After imposing multiple regulations on women, Taliban has now shifted its focus on moral policing Afghan men. The Islamic extremist group is now detaining men and their barbers over hairstyles. They ...

None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of patients in the control group.

Learn more about whether Alvotech or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Taliban’s morality police have detained men and their barbers over hairstyles, and others for missing prayers at mosques during Ramadan, a UN report said on Thursday, 6 months after laws ...